Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

Core Viewpoint - The appointment of Joseph Hand as General Counsel and Executive Vice President of Operations at Tonix Pharmaceuticals is a strategic move as the company prepares for the potential approval of TNX-102 SL for fibromyalgia management next quarter [1][2]. Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on developing therapies for pain management and vaccines for public health challenges, with a particular emphasis on central nervous system (CNS) disorders [3]. - The company is advancing TNX-102 SL, a product candidate for fibromyalgia management, for which a New Drug Application (NDA) has been submitted based on two statistically significant Phase 3 studies [3]. - The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing authorization for TNX-102 SL, which has also received Fast Track designation [3]. Leadership Experience - Joseph Hand brings over 20 years of strategic legal and business leadership experience in the biopharmaceutical industry, including nearly a decade at Celgene Corporation, where he held senior executive positions [1][2]. - At Celgene, Mr. Hand was involved in significant transactions, including the $74 billion acquisition by Bristol Myers Squibb and the $13.4 billion divestiture of Otezla to Amgen [2]. Strategic Importance - The addition of Mr. Hand is seen as crucial for driving company growth and operational excellence at a pivotal time in Tonix's history, particularly as it prepares for the launch of TNX-102 SL [2]. - The company aims to position itself for long-term growth while delivering meaningful therapies to patients [3]. Development Portfolio - Tonix's development portfolio includes biologics targeting organ transplant rejection, autoimmunity, and cancer, such as TNX-1500, an Fc-modified humanized monoclonal antibody [3]. - The company is also developing a vaccine for mpox, TNX-801, and has secured a contract with the U.S. Department of Defense for up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent [3].